Search
Vusolimogene oderparepvec
go.drugbank.com/drugs/DB23008ApprovedInvestigationalon anti-PD-1 therapy. … on a PD-1-blocking antibody-based regimen.
Glycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalChemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
OSU-6162
go.drugbank.com/drugs/DB19178InvestigationalOSU-6162 is under investigation in clinical trial NCT05641623 (OSU6162 as Add-on in Ssri/snri-resistant Depression).
Categories: Dopamine D2 Receptor AntagonistsXMT-1001
go.drugbank.com/drugs/DB06069InvestigationalXMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human tumor xenografts models … In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal).
Categories: Compounds used in a research, industrial, or household settingVorapaxar
go.drugbank.com/drugs/DB09030ApprovedBy inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation. … Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history
Synonyms: Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester, Ethyl N-[(3R,3aS,4S,4aR,7R,8aR,9aR)-4-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3H-benzo[f]isobenzofuran-7-yl]carbamateLycopene
go.drugbank.com/drugs/DB11231ApprovedTomato lycopene extract is used as a color additive in food products. … Lycopene is a naturally occurring red carotenoid pigment that is responsible for red to pink colors seen in tomatoes, pink grapefruit, and other foods [A27242].
Categories: Compounds used in a research, industrial, or household settingPirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalIts high selectivity has been associated with lower discontinuation rates due to adverse events and a lower incidence of atrial fibrillation. … A256758] Unlike BTK covalent inhibitors, such as [ibrutinib], that bind to the cysteine 481 (Cys481) amino acid within the active site of BTK, the inhibitory activity of pirtobrutinib is maintained even in
L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal
go.drugbank.com/drugs/DB06124ExperimentalC-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal
Sofpironium
go.drugbank.com/drugs/DB19325Approved[L51103,L51108] It has also been available in Japan since 2020 under the brand name Ecclock.[L51103] … [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis.
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigational[L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016. … [A229313] Trilaciclib was granted FDA approval on 12 February 2021.[L31823]